Bill To Lower Biologics Exclusivity Period Characterized As Unrelated To TPP

A bipartisan bill to lower the exclusivity period for biologic drugs in the United States from 12 to seven years is being characterized as an attempt to cut costs on life-saving medicines, with supporters and detractors of the legislation refuting any connection to the ongoing fight over the period of exclusivity for biologic drugs required by the Trans-Pacific Partnership. Introduced on June 23 in the Senate by Finance Committee member Sherrod Brown (D-OH) and Sen. John McCain (R-AZ), and in...